Literature DB >> 15690994

Dimension reduction in the linear model for right-censored data: predicting the change of HIV-I RNA levels using clinical and protease gene mutation data.

Jie Huang1, David Harrington.   

Abstract

With rapid development in the technology of measuring disease characteristics at molecular or genetic level, it is possible to collect a large amount of data on various potential predictors of the clinical outcome of interest in medical research. It is often of interest to effectively use the information on a large number of predictors to make prediction of the interested outcome. Various statistical tools were developed to overcome the difficulties caused by the high-dimensionality of the covariate space in the setting of a linear regression model. This paper focuses on the situation, where the interested outcomes are subjected to right censoring. We implemented the extended partial least squares method along with other commonly used approaches for analyzing the high-dimensional covariates to the ACTG333 data set. Especially, we compared the prediction performance of different approaches with extensive cross-validation studies. The results show that the Buckley-James based partial least squares, stepwise subset model selection and principal components regression have similar promising predictive power and the partial least square method has several advantages in terms of interpretability and numerical computation.

Mesh:

Substances:

Year:  2004        PMID: 15690994     DOI: 10.1007/s10985-004-4776-8

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  13 in total

1.  Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases.

Authors:  I C Marschner; R A Betensky; V DeGruttola; S M Hammer; D R Kuritzkes
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1999-03-01

2.  Mixed effects models with censored data with application to HIV RNA levels.

Authors:  J P Hughes
Journal:  Biometrics       Date:  1999-06       Impact factor: 2.571

3.  Iterative partial least squares with right-censored data analysis: a comparison to other dimension reduction techniques.

Authors:  Jie Huang; David Harrington
Journal:  Biometrics       Date:  2005-03       Impact factor: 2.571

4.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

5.  Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333.

Authors:  M F Para; D V Glidden; R W Coombs; A C Collier; J H Condra; C Craig; R Bassett; R Leavitt; S Snyder; V McAuliffe; C Boucher
Journal:  J Infect Dis       Date:  2000-08-14       Impact factor: 5.226

6.  Linking gene expression data with patient survival times using partial least squares.

Authors:  Peter J Park; Lu Tian; Isaac S Kohane
Journal:  Bioinformatics       Date:  2002       Impact factor: 6.937

7.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Authors:  J H Condra; W A Schleif; O M Blahy; L J Gabryelski; D J Graham; J C Quintero; A Rhodes; H L Robbins; E Roth; M Shivaprakash
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

8.  In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies.

Authors:  H Jacobsen; M Hänggi; M Ott; I B Duncan; S Owen; M Andreoni; S Vella; J Mous
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

9.  Partial least squares proportional hazard regression for application to DNA microarray survival data.

Authors:  Danh V Nguyen; David M Rocke
Journal:  Bioinformatics       Date:  2002-12       Impact factor: 6.937

10.  Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.

Authors:  A C Collier; R W Coombs; D A Schoenfeld; R L Bassett; J Timpone; A Baruch; M Jones; K Facey; C Whitacre; V J McAuliffe; H M Friedman; T C Merigan; R C Reichman; C Hooper; L Corey
Journal:  N Engl J Med       Date:  1996-04-18       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.